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High-dose glucocorticosteroids increase the procoagulant effects of
OKT3. The use of OKT3 as prophylaxis in renal transplantation carries an
increased risk of intragraft thrombosis, which is related to the systemic
activation of the coagulation system that consistently occurs after the first
dose of OKT3, As only a few patients develop thrombosis after OKT3
therapy, we searched for possible additional risk factor by comparing the
demographic and clinical parameters of the 13 patients who developed
thrombosis in our institution to those of 218 patients who did not.
Multivariate analysis showed a relationship between the dose of methyl-
prednisolone (mPDS) given before the first OKT3 injection and the risk of
thrombosis: 6 out of 42 patients (14%) who received high (30 mg/kg)
mPDS experienced a thrombotic event, as compared to 7 out of the 189
patients (3.7%) who received 8 mg/kg of mPDS (P < 0.01). This led us
to study the effects of mPDS on the procoagulant activity induced by
OKT3 on peripheral blood mononuclear cells (PBMC) in vitro. The
procoagulant activity of unstimulated PBMC (mean suM: 0.6 0.1
mU/ml) reached 3.0 0.7 mU/mi after OKT3 stimulation (P = 0.0062)
and further increased to 7.4 2.0 mU/ml when PBMC were first
preincubated overnight with mPDS before OKT3 stimulation (P = 0.018
as compared to OKT3 alone). This process involved the tissue factor!
factor VII pathway, as shown by increased membrane expression of tissue
factor on monocytes as well as by a marked reduction of the induced
procoagulant activity when the clotting assay was performed with factor
VU-deficient plasma. We conclude that high-dose mPDS represents a
major risk factor for thrombosis after OKT3 prophylaxis, probably be-
cause of the ability of mPDS to potentiate OKT3-induced tissue factor
expression and activity on monocytes.
OKT3, the murine monoclonal antibody (MoAb) directed
against the chain of the TCR-CD3 complex, is presently the
most potent agent to treat acute renal graft rejection episodes [1,
2]. As far as prophylaxis is concerned, recent data indicate that the
use of OKT3 in high-risk recipients results in a significant
improvement in long-term graft survival as compared to cyclospo-
rin A (CsA) [3—5].
However, the first injection of OKT3 is associated with a
massive leukocyte activation resulting in cytokine release and in
the well-known OKT3 first dose reactions [6, 7]. Triggering of the
extrinsic pathway of the coagulation system also occurs after the
first OKT3 dose, and this may precipitate early intragraft throm-
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bosis eventually resulting in early transplant loss [8—10]. The
thrombotic events observed at our institution occurred most often
in the course of the first post-transplant week and involved either
renal arteries, veins, or glomerular capillaries [8].
The mechanisms underlying the procoagulant effects of OKT3
are twofold. Firstly, OKT3 triggers a systemic release of TNF-a
which induces tissue factor-mediated procoagulant activity on
endothelial cells [9]. Secondly, monocytes stimulated by OKT3
also display an increased expression of tissue factor [11, 12]. This
process involves signals mediated by adhesion molecules [13]
and/or the production by T cells of macrophage procoagulant
inducing factor, an as yet uncompletely characterized cytokine
[14, 15]. Once expressed, tissue factor will bind factor Vil/Vila
and initiate the extrinsic pathway of the coagulation system.
Although all patients display transient systemic activation of the
coagulation system after injection of the first OKT3 dose, only a
small number develop intragraft thrombosis. The aim of the
present study was to identify risk factors for thrombosis after
OKT3 prophylaxis in renal transplant recipients. For this purpose,
we first reviewed the demographic and clinical characteristics of
231 patients who received a prophylactic course of OKT3 at our
institution. As we found that pretreatment with high dose of
methyl-prednisolone (mPDS) before the first OKT3 injection was
associated with an increased incidence of thrombotic events, we
studied the effects of mPDS on OKT3-induced procoagulant
activity of monocytes.
Methods
Patients
The charts of the 231 kidney transplant recipients who received
OKT3 prophylaxis at our institution were reviewed, and the main
demographic parameters, the possible risk factors for thrombosis
and the therapy were recorded. Basal immunosuppression con-
sisted of OKT3, azathroprine (2 mg/kg) and corticosteroids, with
introduction of CsA on post-operative day (POD) 11. During the
period under study (from September 1987 to July 1992), the
following variations were made to therapy: dose of first OKT3
injection (5 or 10 mg); day of first OKT3 injection (POD 0 or 1);
dose of mPDS given before the first OKT3 injection (1, 8, or 30
mg/kg); intravenous administration (or not) of diltiazem, a calci-
um-channel blocker, on POD 0 (according to the protocol of
Wagner, Albrechts and Neumayer [16]). The possible impact of
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these changes in therapy on the occurrence of thrombosis was
studied by univariate and multivariate analysis (see below).
Induction of procoagulant activity on peripheral blood
mononuclear cells
Peripheral blood mononuclear cells (PBMCs) from healthy
volunteers isolated by Ficoll-Hypaque were assayed separately
after culture (3 X 106/ml) in polypropylene tubes in RPM! 1640
medium supplemented with 10% fetal calf serum (endotoxin
content less than 2 pg/ml). PBMC were cultured overnight in
medium alone or containing graded doses of mPDS, washed, and
then stimulated by OKT3 (10 ng/ml). Procoagulant activity and
flow cytometric analysis were determined six hours after OKT3
stimulation (see below).
Procoagulant activity assay
Procoagulant activity on the surface of PBMCs was determined
in duplicate by a single stage clotting assay. Each experiment was
performed with PBMC isolated from different donors. One
hundred microliters of the cell culture suspension (16% to 22%
monocytes as determined by Coulter counter analysis) were
washed in Hanks balanced salt solution Ca and Mg free and
incubated for one minute with 100 p1 of normal citrated plasma
before the initiation of clotting by the addition of 100 p1 of 25
mmolJl CaC12. Clotting time was recorded with a KC10 apparatus
(Amelung, Lemgo, Germany), and procoagulant activity was
determined by reference to a standard curve generated with serial
dilutions of a commercial rabbit thromboplastin. (Excel Sa,
Organon Teknica, Durham, North Carolina, USA). The amount
of thromboplastin that yielded a clotting time of 12.4 seconds was
assigned a value of one unit. To determine the role of the tissue
factor/factor VII pathway in the procoagulant activity, factor
Vu-deficient plasma was used or a blocking anti-factor VII MoAb
was added during the clotting assay (12Db, Centocor, Malvern,
California, USA).
Flow cytometly analysis
Cells harvested from cultures were washed, incubated for 30
minutes with fluoresceinated anti-tissue factor MoAb (500 jLg/ml,
10 jd/test; Murine IgGi MoAb 4508CJ, American Diagnostica
Inc., Greenwich, Connecticut), and analyzed by flow cytometry
using a FACScan (Becton Dickinson, Mountain View, California,
USA). Monocytes were gated by forward and side scatter prop-
erties so that tissue factor-positive cells represented about 70% to
80% of gated cells. In some experiments, double staining was
performed with the fluoresceinated anti-tissue factor MoAb and a
phycoerythrin-labeled anti-CD14 MoAb (20 p1/test; LeuM3, Bec-
ton Dickinson) to identify monocytic cells using a life gate based
on CD14 fluorescence.
TNF-a assay
The amount of TNF-a present in 24 hour supernatants of
PBMC stimulated by OKT3 with or without mPDS pretreatment
was assayed in duplicate by an IRMA kit purchased from Med-
genix (Fleurus, Belgium).
Statistical analysis
Numerical variables (shown as mean SEM) were compared by
Student's t-test, and categorical variables by the Chi square test or
by Fisher's exact test. In order to avoid confusion between
prognostic variables when analyzing demographic and clinical
data from the patients, logistic analysis was performed: the
dichotomous-dependent variable was graft thrombosis (yes/no)
whereas the prognostic-independent variables were either cate-
gorical or numerical. A variable was considered to be significant if
the two-tailed t-test yielded a P value lower than 0.05.
Results
High-dose mPDS pretreatment is an independent risk factor for
intragraft thrombosis after OKT3 prophylaxis.
Table 1 indicates the main demographic parameters, the ther-
apy, and the possible risk factors for thrombosis in the 13 out of
231 patients (5.6%) who developed this complication. Risk factors
for thrombosis found in 6 patients were: transplantation of
kidneys from pediatric donors (N = 2), hemolytic-uremic syn-
drome as primary nephropathy (N = 1), donor kidney large for
recipient size resulting in compression of graft vessels (N = 1),
presence of a lupus anticoagulant (N = 1), and sequella of venous
thrombosis on the iliac vessels used for anastomosis (N = 1).
The main characteristics of the 13 patients with thrombosis
were then compared to those of the 218 patients free of this
complication (Table 2). Recipient and donor age, the number of
blood units received, the duration of dialysis prior to transplan-
tation, cold and warm ischemia times, number of HLA-A, -B and
-DR mismatches, dose (5 or 10 mg) and day (POD 0 or 1) of first
OKT3 injection, number of immunized and retransplanted pa-
tients, as well as the percentage of anti-HLA panel reactive
antibodies among immunized patients were not different between
the two groups by univariate analysis. Two parameters were
significantly different between both groups of patients. First, none
of the patients with thrombosis had received diltiazem on POD 0
(P = 0.043). Second, increasing the dose of mPDS pretreatment
before the first OKT3 injection resulted in an increased incidence
of thrombotic events (P = 0.013).
Only this latter parameter remained significant by multivariate
analysis. Thus, 6 out of 42 patients (14%) who received 30 mg/kg
mPDS pretreatment developed intragraft thrombosis as com-
pared to 7 out of 189 (3.7%) who received 8 mg/kg mPDS dose
(P < 0.01). Of interest, re-examination of the data from Table 1
indicates that only one out of six patients with thrombosis who
received the 30 mg/kg mPDS dose had another risk factor than
high-dose steroids, whereas a definite risk factor for thrombosis
was found in five out of seven patients treated with 8 mg/kg mPDS
(P = 0.1).
Differential effects of mPDS on the procoagulant activity and the
TNF-a production induced by OKT3 in vitro
As mPDS is known to inhibit OKT3-induced TNF-a production
[17—201, we reasoned that the potentiation by mPDS of OKT3
procoagulant activity might occur at the monocyte level. To study
this hypothesis, we used an in vitro model in which we analyzed the
influence of mPDS on the level of procoagulant activity induced
by OKT3 on PBMC from normal donors. As previously observed
[12], addition of OKT3 (10 ng/ml) to cultures of PBMC resulted
in a clear induction of procoagulant activity as assayed after six
hours of incubation. Overnight preincubation of PBMC with
mPDS (1000 ng/ml) followed by washing and addition of OKT3
mPDS 0KT3 0 8 10
+
— +
+ + ____
PCA, mU/mi
2 4 6
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Table 1. Characteristics of patients with intragraft thromboses after OKT3 prophylaxis
HLA First OKT3
Age years Ischemia mismatches injection
Date of PRAC Graft Cold Warm Dose mPDS"
Patient grafting Donor Recipient % no. h mm A B DR Risk factor Day mg mg/kg Diltiazemc
1 09/12/89 1 15 0 1 31 30 1 1 1 Pediatric donor 1 5 8 —
2 15/03/90 38 50 0 1 24 39 1 1 0 — 1 5 8 —
3 01/04/90 53 41 0 1 38 39 2 2 1 HUS as primary
disease
0 10 8 —
4 30/05/90 39 21 0 2 23 27 1 0 0 Large donor
kidney
0 10 30 —
5 06/06/90 29 52 0 2 20 47 1 1 0 — 0 10 30 —
6 30/07/90 35 25 14 3 29 30 1 1 0 — 0 10 30 —
7 03/08/90 44 35 0 1 27 34 0 1 0 — 0 10 30 —
8 23/08/90 19 38 0 1 38 44 1 1 0 — 0 10 30 —
9 19/01/91 35 35 49 1 20 35 1 2 0 — 0 10 30 —
10 13/07/91 41 23 27 1 27 21 2 0 0 Lupus
anticoagulant
0 5 8 —
11 26/07/91 20 40 59 1 17 29 0 0 0 — 0 5 8 —
12 01/11/91 39 48 98 2 20 37 0 1 0 Sequella of
venous
thrombosis on
iliac vessels
0 5 8 —
13 19/05/92 4 29 0 1 30 38 0 1 1 Pediatric donor 1 10 8 —
Percentage of anti-FILA panel reactive antibodies at the time of transplantation
b Dose of methyiprednisolone given before the first OKT3 injection
C Given intravenously on post-operative day 0
Table 2. Intragraft thromboses after OKT3 prophylaxis: Univariate
analysis of 231 patients
Thromboses
PNo Yes
N 218 13 —
Recipient age 35.6 0.7 34.8 3.2 NS
Donor age 33.4 1.0 30.5 4.3 NS
N transfusions 7.88 0.96 6.46 1.61 NS
Dialysis years 3.81 0.17 3.54 0.77 NS
Cold ischemia hr 27.8 0.5 26.7 2.0 NS
Warm ischemia mm 32.3 0.05 34.2 2.0 NS
N mismatches HLA-A 0.92 0.05 0.85 0.19 NS
HLA-B 0.95 0.05 0.92 0.18 NS
HLA-DR 0.34 0.04 0.23 0.12 NS
OKT3 dose 5/10 mg 121/97 5/8 NS
Day of first OKT3 150/68 10/3 NS
dose (0/1)
N immunized patients 42 (19%) 5 (38%) 0.15
N with previous grafts 31(14%) 4 (31%) 0.11
Anti-HLA PRA % 7.5 1.4 19.0 8.7 0.057
Diltiazem yes/no 59/159 0/13 0.043
mPDS mg/kg (1/8/30) 42/140/36 0/7/6 0.013
Numerical values are mean SCM.
for six hours resulted in a marked superinduction of the proco-
agulant activity (7.4 2.0 mU/mi, P = 0.018 vs. PBMC stimulated
by OKT3 in the absence of mPDS preincubation), while incuba-
tion of PBMC with mPDS alone did not influence their basal
procoagulant activity (0.7 0.1 mU/mi; Fig. 1). As shown in
Figure 2, the potentiating effect of mPDS preincubation on
OKT3-induced procoagulant activity was dose-dependent.
Additional experiments showed that the potentiating effect of
mPDS preincubation on OKT3-induced procoagulant activity was
not apparent when mPDS was maintained during the period of
OKT3 stimulation (data not shown).
Fig. 1. Preincubation with methyiprednisolone potentiates OKT3-induced pro-
coagulant activity (PCA). PBMC (7 to 8 experiments with different nor-
mal donors) assayed separately were cultured overnight with or without
methyiprednisolone (1000 ng/ml), washed, and further incubated for 6
hours with OKT3 (10 ng/mi) before determination of the procoagulant
activity in a single-stage clotting assay. Results are shown as mean + SEM.
= 0.0062vs. control PBMC; P = 0.018 vs. OKT3-stimulated PBMC.
We next determined under the same experimental conditions
the effects of mPDS preincubation on OKT3-induced TNF-a
secretion. As shown in Figure 3, while mPDS preincubation
increased OKT3-induced procoagulant activity it strongly inhib-
ited OKT3-induced TNF-a production.
The increased procoagulant activity induced by mPDS on OKT3-
stimulated PBMC is due to tissue factor
Previous experiments have shown that the procoagulant activity
induced by OKT3 alone on PBMC was of the tissue factor type
[12]. Increased tissue factor activity was also responsible for the
enhanced procoagulant activity on PBMC induced by the com-
bined effects of OKT3 and mPDS. Indeed, use of factor VII-
deficient plasma or addition of blocking anti-factor VII MoAb
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Fig 3. Methylprednisolone differentially modulates OKT3-induced proco-
agulant activity ( PCA) and TNF-a () secretion. PBMC were cultured
overnight with mPDS (1000 ng/ml), washed, and further incubated with
OKT3 before determination of procoagulant activity after 6 hours and of
TNF-a content of 24-h culture supernatants. One experiment out of 2
performed.
during the clotting assay markedly reduced the increase in proco-
agulant activity (Table 3).
We next studied whether the synergistic effect of mPDS on
OKT3-induced tissue factor activity on PBMC was associated with
enhanced tissue factor expression on monocytes. As shown in
Table 4, onlybackground levels of tissue factor antigen expression
were present on unstimulated lymphocytes or monocytes, the
latter cells being identified by membrane expression of the CD14
antigen. Stimulation with OKT3 alone markedly increased tissue
factor expression on monocytes, and a further increase was seen
with mPDS preincubation (Fig. 4). In both situations, this process
remained confined to monocytes (Table 4).
Procoagulant activit? assayed with
Factor VII- Normal plasma
Normal deficient + anti-factor
Culturea plasma plasma VII MoAbC
PBMC 0.9 1.0 0.1
PBMC + OKT3 6.1 2.1 0.9
PBMC + mPDS + OKT3 16.7 1.8 2.5
a PBMC were cultured overnight with or without mPDS (1000 ng/ml),
washed, and further incubated for 6 hours with OKT3 (10 nglml) before
determination of procoagulant activity. One representative experiment
out of three performed.bExpressed in mU/mi
C Added at a concentration of 10 .tg/ml
Culturea
Tissue factor expressionb
CD14 cells CD14 cells
PBMC 339 387
PBMC
PBMC
+ OKT3
+ mPDS + OKT3
326
327
488
563
a PBMC were cultured overnight with or without mPDS (1000 ng/ml),
washed, and further incubated for 6 hours with OKT3 (10 ng/ml) before
double-staining with anti-tissue factor and anti-CD14 monoclonal anti-
bodies to identify monocytes. One representative experiment out of 3
performed.bExpressed as mean fluorescence intensity
Discussion
The clinical part of this study identifies the administration of
high doses of methylprednisolone as a major risk factor for the
occurrence of intragraft thromboses under OKT3 prophylaxis.
The in vitro experiments suggest that this might be related to the
ability of mPDS to synergize with OKT3 in the induction of
procoagulant activity on monocytes.
The ability of mPDS to increase the expression of monocytic
tissue factor by OKT3 markedly differs from the classical suppres-
sion of monocytic functions by glucocorticosteroids. Indeed, these
agents powerfully inhibit the production of cytokines by activated
monocytes [21, 22]. This was also the case in the present study, as
mPDS strongly inhibited OKT3-induced TNF-a production by the
same PBMC which displayed increased tissue factor activity. Our
findings are strikingly similar to those of Bottles and Morrissey,
who recently found that the glucocorticosteroid dexamethasone
strongly up-regulated tissue factor activity of monocytes activated
by lipopolysaccharide in vitro, while at the same time dexameth-
asone reduced the LPS-induced TNF-a secretion [23].
Why the triggering effect of mPDS preincubation on the
induction of tissue factor by OKT3 was not seen when mPDS was
present during OKT3 stimulation is presently unknown. However,
this might be related to the ability of glucocorticosteroids to
regulate protein synthesis at multiple levels, both positively and
negatively [24]. Thus, while the potentiating effect of mPDS on
tissue factor membrane expression is probably due to increased
levels of tissue factor mRNA [23], any possible concomitant
inhibition by mPDS of protein synthesis distal to this step would
explain that the potentiating effect of mPDS only becomes
PCA, mU/mi
0 1 2 3 4 5
I I
Table 3. Tissue factor activity is responsible for the enhancement by
methylprednisolone of OKT3-induced procoagulant activity on PBMC
mPDS
ng/mi
1000
100
10
0.1
0.01
Fig 2. Potentiation by methyiprednisolone of OKT3-induced procoagulant
activity (PCA) is dose-dependent. PBMC were cultured overnight with
various doses of mPDS, washed, and further incubated for 6 hours with
OKT3 before determination of procoagulant activity. One representative
experiment out of 4 performed. Symbols are: (D) control; () OKT3.
Table 4. Monocytes display increased tissue factor expression after
stimulation of PBMC with OKT3, mPDS, or both agents
E
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Fig 4. Methylprednisolone increases the OKT3-induced membrane tissue factor expression on monocytes. PBMC were cultured overnight with or without
mPDS (1000 ng/ml), washed, and further incubated for 6 hours with OKT3. Cells harvested from cultures were double-stained with anti-tissue factor
and anti-CD14 monoclonal antibodies to identify monocytes. Histograms of the mean fluorescence intensity (MFI) for tissue factor on CD14 cells are
shown. Left panel, PBMC cultured alone (MFI: 11); middle panel, PBMC cultured with OKT3 (MFI: 67); right panel: PBMC cultured with mPDS and
OKT3 (MFI: 132). One representative experiment out of 3 performed.
apparent after its withdrawal. Such a phenomenon has already
been observed with cycloheximide, which ability to induce tissue
factor protein expression is only seen after washing has allowed
for the cycloheximide inhibition of translation to vanish [25].
While detailed analysis of the in vivo metabolism of mPDS and
of its multiple sites of action at the monocyte level would be
required to definitely establish the relevance of our in vitro
experiments to the in vivo situation, data from several experimen-
tal systems indicate that high-dose glucocorticosteroids can tip the
balance towards sustained coagulation and platelet aggregation.
Indeed, in addition to their ability to increase tissue factor activity
on stimulated macrophages and monocytes [23, 26, 27], they also
inhibit the fibrinolytic system by decreasing the production of
plasminogen activator by several cell types [28—30] while increas-
ing at the same time the secretion of plasminogen activator
inhibitor-i [31]. Glucocorticoids might also promote thromboses
by down-regulating the production of the two anti-aggregant
mediators prostacyclin [32, 33] and nitric oxide [34, 35]. Evidence
that the procoagulant effects of glucocorticosteroids can affect the
kidneys is attested by the extensive thromboses that occur in the
glomerular capillaries of rabbits pretreated with large doses of
steroids before endotoxin challenge during the generalized
Schwartzman reaction [27, 36].
The rationale that some patients from our series received the
high (30 mg/kg) mPDS pretreatment dose was the hope, based on
data from a murine model of OKT3 toxicity, to further reduce
cytokine release and thereby to attenuate OKT3 first dose reac-
tions [37]. Although TNF-a levels were somewhat lower in kidney
transplant recipients treated with 30 mg/kg than with the 8 mg/kg
mPDS dose, the production of this cytokine remained high after
OKT3 injection [38]. It is thus possible that the high steroid dose
favored increased tissue factor activity on monocytes on one hand,
while the persistence of TNF-a secretion still allowed the induc-
tion of tissue factor on endothelial cells on the other hand. Along
this line, high-dose steroid pretreatment in rabbits injected with
endotoxin allowed for reduced TNF-a secretion, although dissem-
inated microthromboses were induced [27].
What is the real risk of thrombosis after OKT3 prophylaxis in
renal transplantation? All patients injected with this agent display
systemic activation of the coagulation system [8—10], but it appears
from the present series that high-dose mPDS represents one
important precipitating factor. This contention would be strength-
ened if increased procoagulant activity could be detected on
monocytes isolated from patients pretreated with high-dose
mPDS. However, the present report renders such a prospective
study unacceptable for ethical reasons. In any case, the fact that
distinct prothrombotic conditions were present in most patients
who developed thrombosis after receiving the regular 8 mg/kg
mPDS pretreatment dose suggests that the intrinsic risk of OKT3
prophylaxis would be low if triggering factors are avoided. This is
supported by the present low incidence of thromboses in our
department (2 among our last 115 kidney transplantations), a
figure now comparable to the 2% incidence of this complication
reported after kidney transplantation [39, 40]. Whatever the
efficiency of the measures used to prevent this and other side
effects of OKT3, the persistent threat of serious reactions at the
initiation of therapy remains [41]. The availability of non-activat-
ing anti-CD3 monoclonal antibodies [42-45] should encourage
clinical trials with these agents in view of the considerable increase
in graft survival afforded by OKT3 in patients at high immuno-
logical risk [3-5].
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